Switch to BIC-TAF-FTC in Women with Virologic Suppression

**GS-380-1961**
Switch to BIC-TAF-FTC in Women with Virologic Suppression
GS-380-1961: Design

**Background**: Randomized, phase 3, multicenter, open label, active-controlled study evaluating the efficacy and safety of switching women with HIV and viral suppression to BIC-TAF-FTC versus continuing their baseline regimen.

**Inclusion Criteria**
- Women aged ≥18 years
- HIV RNA <50 copies/mL for at least 12 weeks
- *EVG/c/TAF/FTC, EVG/c/TDF/FTC, or ATV/r + TDF/FTC
- eGFR >50 mL/min
- No suspected resistance to study drugs
- Using contraception if child-bearing potential
- Chronic hepatitis B or C allowed
*Regimens: 53% EVG/c/TAF/FTC and 42% EVG/c/TDF/FTC

**Switch Regimen**
Bictegravir-TAF-FTC
(n = 234)

**Maintain Regimen**
INSTI or PI-Based Regimen
(n = 236)

Switch to BIC-TAF-FTC in Women with Virologic Suppression GS-380-1961: Results by U.S. FDA Snapshot Algorithm

Interpretation: "Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide provides a safe and efficacious option for ongoing treatment of HIV in women. This study contributes important data on safety, tolerability, and outcomes of antiretroviral therapy among women living with HIV."
The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.